Vistagen Therapeutics Inc.
VTGN
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.83M
Close$
$0.71
184.9% upside
Current Fair Value
184.9% upsideUndervalued by 184.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.83 Million |
|---|---|
| Enterprise Value | $-5,146,036.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.83 |
| Beta | 0.38 |
| Outstanding Shares | 42,980,174 |
Return
| Return on Equity | -276.21% |
|---|---|
| Return on Assets | -189.22% |
| Return on Invested Capital | -283.29% |
Valuation & Multiples
| P/E Ratio | -0.14 |
|---|---|
| PEG | 1.05 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -2.06 |
| Enterprise Value to EBIT | 0.07 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.2 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
$500,000
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
$500,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0691▼ 64.55% |
|---|---|
| Total Calls | 516,800▼ 50.08% |
| Total Puts | 35,700▼ 95.17% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 38.69%▲ 6.13% |
|---|---|
| Total Invested | $8.12M▼ 8.05% |
| Investors Holding | 61▼ 3.00% |
ESG Score
No data
About VistaGen Therapeutics Inc
21 employeesVistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CN...